Niva Bupa Health Insurance Company Ltd
NSE: NIVABUPA BSE: 544286Finance
Incorporated in 2008, Niva Bupa Health Insurance Ltd is a Tech driven leading health insurer in India.[1]
₹80
52W: ₹67.5 — ₹95.2
PE 113 · Book ₹20.5 · +290% vs bookMarket Cap₹14,780 Cr
Stock P/E113Price to Earnings
ROCE3.45%Return on Capital
ROE3.82%Return on Equity
Div. Yield0%Face Value ₹10
Strengths
- +Company is almost debt free.
- +Company has delivered good profit growth of 35.9% CAGR over last 5 years
Weaknesses
- −Stock is trading at 3.91 times its book value
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Tax rate seems low
- −Company has a low return on equity of 5.64% over last 3 years.
Shareholding Pattern
Promoters55.36%
FIIs10.6%
DIIs16.49%
Public17.56%
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 55.98% | 55.98% | 55.43%▼0.5 | 55.41%▼0.0 | 55.36%▼0.0 | 55.36% |
| FIIs | 8.85% | 8.9%▲0.1 | 10.76%▲1.9 | 10.72%▼0.0 | 10.31%▼0.4 | 10.6%▲0.3 |
| DIIs | 9.82% | 9.71%▼0.1 | 15.06%▲5.3 | 15.31%▲0.3 | 16.04%▲0.7 | 16.49%▲0.4 |
| Public | 25.36% | 25.42%▲0.1 | 18.74%▼6.7 | 18.57%▼0.2 | 18.27%▼0.3 | 17.56%▼0.7 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,026 | 1,316 | 1,124 | 1,321 | 1,258 | 1,671 | 1,371 | 1,574 | 1,611 | 2,139 |
| Expenses | 1,071 | 1,215 | 1,228 | 1,387 | 1,282 | 1,420 | 1,464 | 1,627 | 1,705 | 1,773 |
| Operating Profit | -46 | 100 | -103 | -66 | -24 | 251 | -93 | -53 | -94 | 365 |
| OPM % | -4% | 8% | -9% | -5% | -2% | 15% | -7% | -3% | -6% | 17% |
| Net Profit | 5 | 157 | -19 | 13 | 13 | 206 | -91 | -35 | -88 | 345 |
| EPS ₹ | 0 | 0 | 0 | 0 | 0.07 | 1.13 | -0.5 | -0.19 | -0.47 | 1.87 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹6,695Cr, up 24.6% YoY. OPM at 2%.
Debt Position
Borrowings at ₹250Cr. Debt-to-equity ratio: 0.13x. Healthy balance sheet.
Institutional Flow
DIIs: 16.49% (+6.67pp change). FIIs: 10.6% (+1.75pp change). Promoters hold 55.36%.
Margin & Efficiency
ROCE improving from 0% (Mar 2019) to 3% (Mar 2026). Working capital days: -322.
Valuation
PE 113x with 3.45% ROCE. Price is 290% above book value of ₹20.5. Dividend yield: 0%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 2d - Allotment of 3,00,500 Equity shares of May 15, 2026
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 13 May - Transcript of the Earning call held on May 08, 2026
- Announcement under Regulation 30 (LODR)-Newspaper Publication 11 May
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 8 May - Company hosted audio recording of May 8, 2026 earnings call for Q4 and FY2026 results.
- Grant Of Stock Options 8 May - Board appointed two non-executive directors, elevated Ankur Kharbanda to Deputy CEO, approved 12.25 million ESOPs, noted two resignations.
- Financial Year 2025 from bse
- Rating update 27 Jun 2025 from care
- Rating update 2 Jul 2024 from care